NUVO yields 1176.47% · PFE yields 6.13%● Live data
📍 NUVO pulled ahead of the other in Year 1
Combined, NUVO + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NUVO + PFE for your $10,000?
Holdco Nuvo Group D.G Ltd engages in the research, development, and marketing of medical devices for pregnancy monitoring in Israel, the United States, and internationally. It provides INVU platform, a remote pregnancy monitoring platform that provides expectant mothers with a self -administered wireless sensory band, which enables them and their obstetricians to monitor maternal and fetal heart rate, and maternal uterine activity at home and in the clinic from the 32nd week of pregnancy until the beginning of labor. The company's INVU platform includes a wireless sensory band with multi-modality technology to capture signals to enable the INVU platform; and a cloud computing environment that processes and analyzes data and transmits personalized reports on maternal and fetal health metrics to the expectant mother and her obstetrician through digital visualization tools. It has a collaboration with Royal Philips and Charité Universitätsmedizin Berlin. The company was formerly known as Nuvo Group Ltd. and changed its name to Holdco Nuvo Group D.G Ltd in May 2024. Holdco Nuvo Group D.G Ltd incorporated in 2006 and is headquartered in Tel Aviv, Israel. On August 22, 2024, Holdco Nuvo Group D.G Ltd filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Full NUVO Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.